| Description | Teriflunomide (A 77-1726) is the principal active metabolite of leflunomide, an approved therapy for rheumatoid arthritis and multiple sclerosis. |
| In vitro | Teriflunomide 主要通过抑制二氢乳酸脱氢酶(DHODH)，参与快速增殖细胞中的嘧啶核苷酸的新生合成作用。通过降低高亲和力增殖的 T 淋巴细胞和 B 淋巴细胞的活性，teriflunomide 很可能减缓 MS 中对自身抗原的炎症反应。值得注意的是，DHODH 的阻断不会影响处于静息状态或通过"拯救途径"能够产生嘧啶池的造血细胞系的家庭式增殖，这一途径不依赖于DHODH。因此，teriflunomide 可被视为对白细胞的细胞静止化合物而非细胞毒性化合物[1]。 |
| Synonyms | A 77-1726, 特立氟胺 |
| molecular weight | 270.21 |
| Molecular formula | C12H9F3N2O2 |
| CAS | 163451-81-8 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility | DMSO: 26 mg/mL (96.22 mM) |
| References | 1. Paul O , Oh . An update of teriflunomide for treatment of multiple sclerosis[J]. Therapeutics and Clinical Risk Management, 2013:177-. 2. He D , Xu Z , Dong S , et al. Teriflunomide for multiple sclerosis[J]. Cochrane database of systematic reviews (Online), 2012, 12(12):CD009882. |
| Citations | 1. Luo S, Wu F, Fang Q, et al.Antidepressant effect of teriflunomide via oligodendrocyte protection in a mouse model.Heliyon.2024 |